355 related articles for article (PubMed ID: 29878089)
21. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
22. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
23. X-linked hypophosphatemia and growth.
Fuente R; Gil-Peña H; Claramunt-Taberner D; Hernández O; Fernández-Iglesias A; Alonso-Durán L; Rodríguez-Rubio E; Santos F
Rev Endocr Metab Disord; 2017 Mar; 18(1):107-115. PubMed ID: 28130634
[TBL] [Abstract][Full Text] [Related]
24. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
26. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.
Qian C; Ito N; Tsuji K; Sato S; Kikuchi K; Yoshii T; Miyata T; Asou Y
FEBS Open Bio; 2024 Feb; 14(2):290-299. PubMed ID: 38050660
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D supplementation improves bone mineralisation independent of dietary phosphate in male X-linked hypophosphatemic (Hyp) mice.
Barratt KR; Sawyer RK; Atkins GJ; St-Arnaud R; Anderson PH
Bone; 2021 Feb; 143():115767. PubMed ID: 33232838
[TBL] [Abstract][Full Text] [Related]
29. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
30. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia.
Lira Dos Santos EJ; Nakajima K; Po J; Hanai A; Zhukouskaya V; Biosse Duplan M; Linglart A; Shimada T; Chaussain C; Bardet C
Int J Oral Sci; 2023 Dec; 15(1):53. PubMed ID: 38052774
[TBL] [Abstract][Full Text] [Related]
31. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
[TBL] [Abstract][Full Text] [Related]
32. PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.
Zelenchuk LV; Hedge AM; Rowe PS
PLoS One; 2014; 9(5):e97326. PubMed ID: 24839967
[TBL] [Abstract][Full Text] [Related]
33. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
Portale AA; Zhang MY; David V; Martin A; Jiao Y; Gu W; Perwad F
PLoS One; 2015; 10(11):e0142924. PubMed ID: 26588476
[TBL] [Abstract][Full Text] [Related]
34. 1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice.
Martins JS; Liu ES; Sneddon WB; Friedman PA; Demay MB
Endocrinology; 2019 Oct; 160(10):2204-2214. PubMed ID: 31237611
[TBL] [Abstract][Full Text] [Related]
35. Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets.
Razali NN; Hwu TT; Thilakavathy K
J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1009-17. PubMed ID: 25894638
[TBL] [Abstract][Full Text] [Related]
36. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
37. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
39. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
40. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
